Paul Hastings advised FACT II Acquisition Corp. on the offering. FACT II Acquisition Corp. announced the pricing of its initial public offering of 17,500,000 units at...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Kyverna Therapeutics in connection with the company’s upsized initial public offering. Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell...
You must be a Standard 1 Year member to access this content.
Paul Hastings and NautaDutilh advised Altisource, and The NBD Group advised the underwriter. Altisource Portfolio Solutions S.A. (NASDAQ: ASPS) announced its underwritten public offering of shares...
You must be a Standard 1 Year member to access this content.
